查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
青光眼市场规模/份额/趋势分析报告：按疾病类型、按药物类别、按分销渠道、按地区、细分市场趋势，2023-2030
市场调查报告书
商品编码
1321347

青光眼市场规模/份额/趋势分析报告：按疾病类型、按药物类别、按分销渠道、按地区、细分市场趋势，2023-2030

Glaucoma Market Size, Share & Trends Analysis Report By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma), By Drug Class (Prostaglandins Analogs, Beta-blockers), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

青光眼市场增长和趋势

Grand View Research, Inc.最新报告显示，预计2023年至2030年全球青光眼市场规模将以4.61%的年复合成长率增长，2030年将达到115.2亿美元。

青光眼患病率的上升、个性化治疗策略的采用以及患者意识的提高正在推动市场的增长。以患者为中心的护理在疾病治疗中变得越来越重要。这包括自我管理、患者教育和协作决策等技术。通过教育患者并让患者参与治疗选择，患者对治疗的依从性、治疗满意度和总体结果均得到改善。

青光眼行业拥有强大的产品线，预计将推动未来的增长。例如，据 2023 年 4 月《科学进展杂誌》报导，科学家正在开发新的基因疗法来治疗这种疾病。 Exhaura Ltd 和 Smurfit 遗传学研究所合作开发了该产品。支持新型疗法开发的研发团队的存在预计将推动市场增长。例如，2023年3月，印第安纳大学医学院宣布其眼科正在致力于利用诱导多能干细胞来帮助治疗青光眼。

此外，人口失明发生率的增加使得更多的人选择早期治疗，从而推动了该行业的增长。例如，根据世界卫生组织（WHO）2020年发布的报告，青光眼是仅次于白内障的第二大致盲眼病。据报导，印度有 1190 万人因青光眼而失明。视力丧失的负担日益加重，导致对治疗药物和生物製剂的需求增加，推动行业增长。

患有糖尿病、年龄相关性黄斑部病变（AMD）、白内障和干眼症等眼科疾病的患者更容易患上青光眼。因此，罹患眼科疾病的老年人口不断增加正在推动对青光眼药物的需求。此外，主要企业正在努力通过推出用于治疗这种疾病的新产品来扩大产品系列。例如，2021年3月，Teva Pharmaceuticals USA, Inc.宣布在美国推出首个仿製药1% AZOPT（布林佐胺滴眼液）。本品用于治疗开放性青光眼和高眼压症引起的眼压升高。

青光眼市场报告亮点

  • 按疾病类型划分，由于治疗性生物製剂的市场发展，开放性青光眼细分市场将在 2022 年占据主导地位。
  • 按药物类别划分，前列腺素类似物在 2022 年占据最大的市场份额。
  • 按分销渠道划分，2022年医院药房领域占据最大市场份额。医院药房使患者受益，因为它们易于使用并提供合格的指导。
  • 北美地区占据强大的区域地位，2022 年市场份额为 38.60%。这是由于政府资助增加和治疗采用率提高而导致该地区研发活动增长的结果。
  • 主要参与企业包括辉瑞、参天、诺华、爱尔康、阿克伦运营公司、Thea Pharma、艾伯维、博士伦和梯瓦製药工业公司。

目录

第1章调查方法和范围

  • 市场区隔
  • 目的
  • 调查方法
  • 资讯采购
    • 购买数据库
    • GVR内部数据库
    • 次要资讯
    • 初步调查
  • 资讯或资料分析
    • 资料分析模型
  • 市场形成和检验
  • 型号详情
    • 产品流向分析
  • 二手资讯清单
  • 简称列表
  • 主要资讯清单

第2章执行摘要

第3章市场变量、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母公司市场预测
    • 相关/辅助市场预测
  • 市场动态
  • 市场促进因素
    • 加强行业主要企业之间的协作和伙伴关係
    • 推出创新产品
    • 加强眼科领域的研究和开发
  • 市场抑制因素分析
    • 对疾病缺乏认识和诊断不足
    • 昂贵的治疗费用
  • 营商环境分析
    • SWOT 分析：按因素（政治/法律、经济/技术）
    • 波特五力分析
    • COVID-19 影响分析

第4章疾病业务分析

  • 青光眼市场：疾病类型变化分析
  • 开放性青光眼
    • 开放性青光眼市场，2018-2030
  • 隅角闭锁性青光眼
    • 2018-2030 年隅角闭锁性青光眼市场
  • 其他的

第5章医药类业务分析

  • 青光眼市场：药物类别变化分析
  • 前列腺素类似物市场，2018-2030
  • β 受体阻断药
  • 肾上腺素能激动剂
  • 碳酸酐酶抑製剂
  • 其他的

第6章分销渠道业务分析

  • 青光眼市场：分销渠道波动分析
  • 医院药房
  • 零售药房
  • 网上药房

第7章区域业务分析

  • 2022 年和 2030 年青光眼市场份额（按地区）
  • 北美
    • 北美青光眼市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲青光眼市场，2018-2030
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区青光眼市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 鲷鱼
  • 拉美
    • 拉丁美洲青光眼市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 中东和非洲青光眼市场，2018-2030
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第8章竞争形势

  • 参与企业概况
  • 财务绩效
  • 参与企业
    • 市场领导者
    • 2022 年青光眼市场份额分析
    • 公司简介
    • 战略规划
Product Code: GVR-4-68040-095-0

Glaucoma Market Growth & Trends

The global glaucoma market size is expected to reach USD 11.52 billion by 2030, expanding at a CAGR of 4.61% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of glaucoma, incorporation of individualized treatment strategies and growing patient awareness are driving the market growth. Patient-centered care is becoming increasingly important for the treatment of the disease. This covers techniques for self-management, patient education, and collaborative decision-making. Patients' adherence to treatments, contentment with them, and overall outcomes can all be enhanced by educating them and including them in treatment choices.

The glaucoma industry has a strong pipeline, which is anticipated to fuel future growth. For instance, as per Science Advances Journal in April 2023, scientists are developing a novel gene therapy to treat the disease. The collaboration of Exhaura Ltd and Smurfit Institute of Genetics is developing this product. The presence of research and development teams supporting the development of novel treatments is projected to propel market growth. For instance, in March 2023, IU School of Medicine announced its Department of Opthalmology is working on using induced pluripotent stem cells to aid glaucoma treatment.

Moreover, the increasing incidence of blindness among the population is propelling the industry growth as the more aware population opts for early treatment. For instance, as per the reports published by World Health Organization in 2020, glaucoma was the second major cause of blindness after cataracts. India reported 11.9 million cases of glaucoma-associated blindness. The increasing burden of vision loss led to the increasing demand for therapeutics and biologics, which boosts the industry growth.

Patients with diabetes and other eye conditions, such as Age-related Macular Degeneration (AMD), cataract, and dry eye, are more prone to developing glaucoma. Thus, the growing elderly population, which is highly susceptible to eye diseases is propelling the demand for glaucoma drugs. Moreover, key players are involved in product portfolio expansion with the launch of novel products used to treat the disease. For instance, in March 2021, Teva Pharmaceuticals USA, Inc. announced the launch of the first generic version of 1% AZOPT (brinzolamide ophthalmic solution) in the U.S., which is used to treat high levels of pressure inside the eye caused due to open-angle glaucoma and ocular hypertension.

Glaucoma Market Report Highlights

  • By disease type, the open-angle glaucoma segment dominated the market in 2022 owing to the development of biologics for the treatment of the disease
  • By drug class, the prostaglandin analogs segment held the largest market share in 2022, attributable to their safety and universal acceptance as the first-line treatment option
  • By distribution channel, the hospital pharmacy segment held the largest market share in 2022. The patients benefit from the hospital pharmacy as it provides accessibility and qualified guidance
  • North America has established a strong regional position with a 38.60% market share in 2022. This is a result of the region's R&D activity growing due to increased government funding and a high adoption rate of treatments
  • A few of the key industry players include Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Novartis AG; Alcon Inc.; Akron Operating Company LLC; Thea Pharma; AbbVie, Inc.; Bausch & Lomb Incorporated; and Teva Pharmaceuticals Industries Ltd.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type And Drug Class Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing Collaboration And Partnerships Among The Industry's Key Players
    • 3.4.2. Novel Product Launch
    • 3.4.3. Increasing R&D In The Ophthalmology Sector
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack Of Awareness And Underdiagnoses Of The Disease
    • 3.5.2. High Cost Of The Treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Glaucoma Market: Disease Type Movement Analysis
  • 4.2. Open Angle Glaucoma
    • 4.2.1. Open Angle Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.3. Angle Closure Glaucoma
    • 4.3.1. Angle Closure Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Glaucoma Market: Drug Class Movement Analysis
  • 5.2. Prostaglandins Analogs Market, 2018 - 2030 (USD Million)
  • 5.3. Beta-Blockers
    • 5.3.1. Beta-Blockers Market, 2018 - 2030 (USD Million)
  • 5.4. Adrenergic Agonists
    • 5.4.1. Adrenergic Agonists Market, 2018 - 2030 (USD Million)
  • 5.5. Carbonic Anhydrase Inhibitors
    • 5.5.1. Carbonic Anhydrase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Glaucoma Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Glaucoma Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.3. Uk
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. Uk Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Glaucoma Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's Overview
  • 8.2. Financial Performance
  • 8.3. Participant Categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Glaucoma Market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. Pfizer Inc.
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Santen Pharmaceutical Co., Ltd.
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Novartis Ag
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Akron Operating Company Llc
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Thea Pharma
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbvie, Inc.
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Bausch + Lomb Corporation
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Teva Pharmaceuticals Industries Ltd.
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Alcon Inc.
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Glaucoma Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Canada Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 Europe Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 UK Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 France Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28 France Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Italy Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Italy Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Spain Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Spain Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Denmark Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Denmark Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Sweden Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Sweden Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Norway Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Norway Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 China Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 China Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Japan Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56 India Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 South Korea Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 South Korea Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Australia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65 Thailand Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Latin America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 Brazil Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Mexico Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Mexico Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Argentina Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85 South Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91 UAE Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Glaucoma Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Glaucoma Market: Disease Type Movement Analysis
  • Fig. 17 Global Glaucoma Market, by Open Angle Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 18 Global Glaucoma Market, by Angle Closure Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 19 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Glaucoma Market: Drug Class Movement Analysis
  • Fig. 21 Global Glaucoma Market, by Prostaglandins Analogs, 2018 - 2030 (USD Million)
  • Fig. 22 Global Glaucoma Market, by Beta-blockers, 2018 - 2030 (USD Million)
  • Fig. 23 Global Glaucoma Market, by Adrenergic Agonists, 2018 - 2030 (USD Million)
  • Fig. 24 Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 25 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Glaucoma Market: Distribution Channel Movement Analysis
  • Fig. 27 Global Glaucoma Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 28 Global Glaucoma Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Glaucoma Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 Regional Outlook, 2022 & 2030
  • Fig. 32 Global Glaucoma Market: Region Movement Analysis
  • Fig. 33 North America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 47 China Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 48 India Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Glaucoma Market, 2018 - 2030 (USD Million)